Background
Results
The mean participant age was 70.1±9.4 years; 262 patients (49.2%) were male. The median 25(OH)D 3 level was 19.1±6.9 ng/mL. The prevalence of depression was higher in CKD patients than in the general population (14.3 vs. 11.1%, P = 0.03). Additionally, the prevalence of depression was significantly higher in CKD patients with (vs. without) vitamin D deficiency (32.5% vs. 50.0%, P<0.001). Multivariate logistic regression analysis showed that vitamin D deficiency was a significant independent predictor of depression after adjusting for confounding factors (adjusted odds ratio, 6.15; 95% confidence interval, 2.02-8.75; P = 0.001). a1111111111 a1111111111 a1111111111 a1111111111 a1111111111
Introduction
Depression is reported to be the most common psychological problem in patients with chronic kidney disease (CKD) [1, 2] . The prevalence of depression in patients with CKD is approximately 20-30%, which is higher than that of other chronic diseases [3, 4] . Depression may result in poor quality of life and functional impairment, and may also hinder adherence to medical treatment and impair nutritional status [5, 6] . Accumulating evidence has shown that depressive symptoms in patients undergoing dialysis are independent predictors of adverse clinical outcomes. The Dialysis Outcomes and Practice Patterns Study (DOPPS) showed a significant association between both mortality and hospitalization rates and depressive symptoms [7] . Moreover, high levels of depressive symptoms are found to be correlated with increased risk of cardiovascular events in an analysis from the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) study [8] . Recently, prospective studies found that patients with pre-dialysis CKD who experienced episodes of major depression were more likely to progress to dialysis [9, 10] .
Serum 25-hydroxyvitamin D 3 [25(OH)D 3 ] levels begin to decrease in stage 2 CKD [11, 12] , and deficiency of serum 25(OH)D 3 is present in all subsequent stages of CKD [13] [14] [15] [16] [17] , including end-stage renal disease (ESRD). Proteinuria may be accompanied by high urinary loss of vitamin D-binding protein, leading to increased renal loss of vitamin D metabolites [14, 18, 19] . Low serum 25(OH)D 3 levels in patients with CKD have been associated with a higher risk of all-cause mortality and faster progression of kidney disease [20] [21] [22] . In the Third National Health and Nutrition Examination Survey (NHANES III) cohort [13] , individuals with 25(OH)D 3 levels lower than 15 ng/mL had a higher risk for all-cause mortality despite adjustments for CKD stage and confounding factors. Such findings have led to investigate on the role of 25(OH)D 3 in multiple chronic diseases [23, 24] , and increase in serologic testing and use of vitamin D supplementation [25, 26] . Various population and clinical research has implicated vitamin D deficiency as a potential risk factor for several chronic diseases, including hypertension, obesity, diabetes, cardiovascular diseases, autoimmune diseases, as well as depression [27] [28] [29] [30] [31] [32] [33] . Therefore, adequate vitamin D levels are a therapeutic goal for patients with kidney disease, in order to prevent several complications [34] .
Several studies have reported that lower levels of serum 25(OH)D 3 are significantly associated with depression [35] [36] [37] [38] . Schneider et al. [39] suggested that psychiatric disorders, especially depression, may be associated with low levels of serum 25(OH)D 3 . Underlying causes of vitamin D deficiency, such as less sun exposure, can result from decreased outdoor physical activity, different housing or clothing habits, and decreased vitamin supplementation [40] . However, depression may also be a consequence of vitamin D deficiency. Serum 25(OH)D 3 deficiency, while common, is highly treatable, which may help prevent depression.
As mentioned above, recent studies have reported the association between vitamin D deficiency and depression in the general population. Even though both vitamin D deficiency and depression are prevalent in patients with CKD, the relationship between these two factors remains poorly elucidated. Therefore, this study aimed to investigate the association between vitamin D levels and depression among patients with CKD.
Methods

Study design, setting, and participants
This study was based on data from the fifth and sixth editions of Korean National Health and Nutrition Examination Survey (KNHANES V, VI, 2010-2014, S1 Data). The KNHANES is a cross-sectional survey conducted periodically to assess the Korean public health and nutritional status. The KNHANES is composed of demographic, anthropometric, nutritional, and personal medical history data collected by trained investigators. Sampling frame was developed based on the multistage probability sampling that was stratified according to geographic location, gender, and age. In the fifth and sixth KNHANES (2010-2014), a total of 41,102 individuals aged ! 1 year were sampled. Among them, 21,257 individuals were screened for this study. Of the screened individuals, we only performed analyses of adults aged ! 19 years ( Fig  1) . We excluded individuals whose data were missing for important analytic variables, such as serum 25 General characteristics of study participants . Demographic variables that were expected to be confounding factors included age, sex, marital status, occupational status, education status, economic status, alcohol behavior, smoking status, and EuroQol five dimensions (EQ5D) index score. Marital status was divided into two groups (single or married) based on questionnaire responses. Occupational status was divided into two groups: employed or unemployed. Education level was divided into three groups: elementary school, middle-high school, or college. Economic status was divided into three groups according to monthly income: low, middle, or high. The EQ5D descriptive system had five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. A multi-attribute value function was used to map preferences for each of these health states. From this scoring algorithm, EQ5D index scores were calculated based on subjects' responses to the five-item questionnaire. Scoring algorithm for the EQ5D index used in this study was based on the Korean value set [41] .
Mental health. Mental health data were obtained by means of a self-reported mental health questionnaire, under the supervision of a trained investigator. Depressive symptoms were assessed by the following question: "In the past year, have you felt extreme sorrow or despair for more than two weeks?" Participants answered either "yes" or "no" to this question. This questionnaire had been used to identify people with depressive mood from the outset of KNHANES (1998) [42] . It is still widely used to measure participants with either clinical or subclinical depressive symptoms, which are expected to be substitutes for depressive disorders. In addition, participants were asked whether they had been diagnosed with depression by a physician. If subjects answered that they were either experiencing depressive symptoms or were currently diagnosed with depression, they were defined as having depression. Finally, participants were divided into two groups according to their answer, ''depressive" or ''nondepressive" group.
Serum 25(OH)D 3 assessment and laboratory data. Blood samples, collected from the antecubital vein after a 10 to 12 hour fast, were used to assess serum levels of biochemical markers. Serum levels of 25(OH)D 3 were measured by gamma counter with a radioimmunoassay (25-hydroxy-vitamin D125 I RIA Kit; DiaSorin, Stillwater, MN, USA) using a 1470 Wizard Gamma Counter (PerkinElmer, Turku, Finland). To make an effort for minimizing the analytical variation, serum 25(OH)D 3 levels were analyzed by the same institute, which carried out a quality assurance program throughout the analysis period. Inter-assay coefficients of variation were 1.9-6.1% for the samples [43] . Participants were divided into two groups according to serum 25(OH)D 3 levels: 25(OH)D 3 deficient group ( 10 ng/mL) and 25(OH)D 3 sufficient group (>10 ng/mL) [44] . In addition, biochemical laboratory test results for the following factors were collected: serum hemoglobin, glucose, total cholesterol, and glycosylated hemoglobin (Hba1c). Proteinuria was determined semi-quantitatively with a single spot urine dipstick analysis and reported as negative, trace, 1+, 2+, 3+, or 4+. Proteinuria was defined as 1+ or higher. The four-variable Modification of Diet in Renal Disease Study equation was used to calculate the eGFR [45] .
Statistical analysis. All statistical analyses were performed using SPSS for Windows version 21.0 (SPSS Inc., Chicago, USA). Continuous variables were expressed as the mean ± standard deviation, and categorical variables as absolute number with percentages. Each variable was tested for normality before statistical analysis. Comparisons between the groups were made by the type of analysis for variance or Student's t-test for continuous variables and by the chi-squared test or Fisher's exact test for categorical variables. The Kolmogorov-Smirnov test was performed to determine the normality of the distribution of parameters. If the resulting data did not show a normal distribution, geometric mean ± standard deviation was reported; Either Mann-Whitney U test or Kruskal-Wallis test was used for multiple comparisons. Logistic regression analysis was done to evaluate the association between depressive symptom and serum 25(OH)D 3 concentration. Odds ratios (ORs) for depressive symptoms were compared between 25(OH)D 3 deficiency group and 25(OH)D 3 sufficiency group. Multiple models were constructed for logistic regression. One was analyzed without adjustment, and others were adjusted for confounding factors including age, sex, smoking status, alcohol status, BMI, suicidal ideation, EQ5D index, past history of hypertension, diabetes mellitus, eGFR, proteinuria, serum glucose, hemoglobin, and total cholesterol level. P values less than 0.05 were considered statistically significant.
Results
Baseline characteristics of CKD patients according to 25(OH)D 3 level
The baseline characteristics of study participants are shown in Table 1 . The mean age was 70.1 ± 9.4 years, and 262 (49.2%) patients were male. The mean 25(OH)D 3 level was 19.1 ± 6.9 ng/mL overall, 8.5 ± 1.3 ng/mL in the vitamin D deficient group, and 19.9 ± 6.5 ng/mL in the sufficient group. The vitamin D deficient group had a greater proportion of female and unemployed patients, and the EQ5D index that represents quality of life was lower. A past history of diabetes was prevalent in the vitamin D deficient group and the serum hemoglobin level was lower in the vitamin D deficient group. However, there were no differences in proteinuria, eGFR, or BMI between the two groups.
Comparison of prevalence of depression between the general population and CKD patients
Chi-square analysis was performed to compare the prevalence of depression between CKD patients and the general population (Fig 2A) . The prevalence of depression was significantly higher in CKD patients compared with the general population (24.4% versus 33.8%, P < 0.001).
Comparison of prevalence of depression between the vitamin D deficient and sufficient groups of CKD patients
We further evaluated the association of depression and vitamin D deficiency in CKD patients. The prevalence of depression was significantly higher in the vitamin D deficient group of CKD patients, compared with those with sufficient levels of vitamin D (32.5% versus 50.0%, P < 0.001, Fig 2B) .
Vitamin D deficiency as a predictor of depression in CKD patients
Logistic regression analysis was performed to investigate the independent association between vitamin D deficiency and depression (Table 2 ). In the crude logistic regression analysis, vitamin D deficiency was significantly associated with depression [OR, 2.08; 95% confidence interval (CI), 1.09-3.98; P = 0.03]. In the multivariate logistic regression analysis, the significant association remained, even after adjustment for factors reported to be associated with depression, such as age, sex, alcohol status, smoking status, suicidal ideation, occupational status, education status, economic status, EQ5D index, past history of hypertension or diabetes, serum hemoglobin level, eGFR, proteinuria, and body mass index (OR, 6.15; 95% CI, 2.02-18.75; P = 0.001).
Subgroup analysis
Subgroup analysis was conducted according to age, sex, EQ5D index, and presence of diabetes (Table 3 ). In the group aged < 65 years, vitamin D deficiency and depression were significantly 
Discussion
This study showed that vitamin D deficiency was significantly associated with depressive symptoms in patients with CKD. Consistent with previous reports, the prevalence of depression was significantly higher in these individuals compared with the general population. Among patients with CKD, depression was more prevalent in the vitamin D deficiency group. Furthermore, vitamin D deficiency was an independent predictor of depression in patients with CKD, even after adjustment for confounders. To the best of our knowledge, this is the first investigation elucidating a relationship between vitamin D deficiency and depressive symptoms in patients with CKD. In this study, the prevalence of depression in CKD subjects was significantly higher compared with the general population. Furthermore, this study showed that vitamin D deficiency was an independent predictor for the presence of depression even after adjustment for multiple confounding factors in CKD patients. Although the cause of depression in patients with CKD is multifactorial, vitamin D deficiency is one of the plausible factors that has recently garnered much interest [46] . Vitamin D is a distinctive neurosteroid hormone and may play an important role in the development of depression. Vitamin D receptors are present extensively on neurons and glia in many areas of the brain, including the cingulate cortex and hippocampus, which have been implicated in the pathophysiology of depression [47] . Vitamin D also promotes the synthesis of depression-related monoamine neurotransmitters, such as serotonin, and is involved in numerous brain processes, including neuroimmuno-modulation, regulation of neurotrophic factors, neuroprotection, neuroplasticity, and brain development, making it biologically reasonable that vitamin D deficiency might contribute to the development of depression [48, 49] . In addition, regarding physical functioning, vitamin D receptors have been observed in the cerebellum, which is an important area of the brain for mobility, gait, and balance [47] , and in muscle tissue, which facilitates muscle contraction speed, muscle power, and cell growth [48] . Vitamin D deficiency might attenuate muscle power and further lead to poor physical functioning. It is well known that reduced physical activity is a risk factor for depression [50] . For reasons mentioned above, vitamin D deficiency can lead to depression.
Several risk factors for vitamin D deficiency have been identified, some of which are also associated with depression. These include aging, female sex, dark skin pigmentation, winter season, obesity, impaired liver function, no use of vitamin D supplements, antidepressant and anticonvulsant medication use, and psychiatric comorbidities such as anxiety or eating disorders [51] . Furthermore, a range of medical conditions, including cardiovascular, liver, and renal disease may be associated with low vitamin D levels [52] . However, to date, even though both vitamin D deficiency and depression are prevalent in patients with CKD, the relationship between these two factors in this group of patients has been poorly elucidated. In this regard, this study is notable in that it is the first to investigate the association between vitamin D deficiency and depression in CKD patients. In this study, CKD patients with low vitamin D levels were older, more likely to have diabetes, and had lower levels of hemoglobin. These factors are known to be markers of poor medical condition. This poor state of health can be one of the risk factors for depressive symptoms. Thus, poor medical condition in the group with vitamin D deficiency could be a reason for the relationship between vitamin D deficiency and depression.
It is well known that the blood level of vitamin D in patients with CKD is low [53] . Limited exposure to sunlight in combination with impaired UVB-induced vitamin D synthesis in the skin and disturbed vitamin D metabolism are considered to contribute to low 25(OH)D 3 levels in patients with CKD [54, 55] . As previously mentioned, vitamin D deficiency is a plausible risk factor for depressive symptoms. According to the results of the present work, the mean serum 25(OH)D 3 level was 19.1 ng/mL in CKD patients. Hence, almost all CKD patients in this study experienced vitamin D insufficiency. Thus, this study showed that in patients with CKD, the prevalence of depressive symptoms is high and, given that vitamin D deficiency in these patients is highly prevalent [53] , management of vitamin D deficiency in CKD is beneficial to prevent the development of depression. A randomized double blind trial reported that supplementation of vitamin D ameliorates depressive symptoms [56] . This result indicates that vitamin D deficiency is associated with depressive symptoms. However, to date, there is no randomized control trial targeting CKD patients investigating the relationship between vitamin D supplementation and depression. Further studies are needed to support the association of vitamin D deficiency and depression. Specifically, subgroup analysis revealed that the strength of associations still had significance in those aged <65 years, in women, in those with no history of diabetes, and the group whose EQ5D index was high. However, among those aged ! 65, with diabetes, or with a low EQ5D index, no association with vitamin D deficiency and depression was demonstrated. This is likely because patients who are older, have a poor medical condition, or have a low EQ5D index have a more complicated condition so that other confounding factors influence the development of depression. However, our results could be generalizable to CKD patients who are young, female, and have less complicated medical disease. Among these patients, screening for vitamin D deficiency might prevent depression.
This study has several limitations. First, as serum vitamin D level is generally affected by the extent of sun exposure, seasonal variation should be considered. However, because the data used in this study could not be linked to specific dates of laboratory measure, seasonal variation could not be included. Second, since the liver is a key organ involved in the metabolism of vitamin D, a history of liver disease may affect vitamin D deficiency. However, in this study, only a few subjects had liver disease; hence, we did not adjust for this. Third, serum PTH level is associated with vitamin D deficiency and depression. Furthermore, it is well-known that active vitamin D metabolite is more significant in CKD patients. However, since KNHANES focused on the basic public nutritional status, it does not provide special laboratory findings such as PTH level and active vitamin D metabolite. Finally, there is paucity of data from randomized control studies on whether supplementation of vitamin D can improve or prevent depression or adverse clinical outcomes. Further randomized control trials should be performed to determine whether vitamin D supplementation could be beneficial to improve depression and adverse clinical outcomes in patients with CKD as well as in the general population.
In conclusion, it is notable that this study demonstrated the association between vitamin D deficiency and depression in CKD patients. Further randomized control trials should be performed to determine whether vitamin D supplementation could be beneficial to improve depression and adverse clinical outcomes in CKD patients as well as in the general population. 
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